Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$8.53−0.23 (-2.68%)

Close on Nov 13, 2026Market cap $1.41BP/E –Yield –

Novavax EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Novavax's EV/EBITDA was 1.2× on Apr 30, 2026.

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	1.2×	+0.2
2025	Dec 31, 2025	0.9×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NVAX.

Revenue growth-61.3% · median 17.7%

Gross margin78.0% · median 63.4%

Operating margin-21.2% · median -38.3%

Net margin-18.6% · median -34.3%

Advertisement
300 × 250

See a number that looks wrong?